Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Cancer Discovery
Angel L Guerrero-Zotano, Carlos L Arteaga

Abstract

Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery.Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs. Cancer Discov; 7(6); 561-74. ©2017 AACR.

References

Dec 1, 1992·The British Journal of Surgery·D J GaskellA P Forrest
Oct 16, 1996·Journal of the National Cancer Institute·D F HayesR J Winn
Feb 3, 2005·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ander UrruticoecheaMitch Dowsett
Dec 31, 2005·The New England Journal of Medicine·UNKNOWN Breast International Group (BIG) 1-98 Collaborative GroupAron Goldhirsch
Jan 18, 2007·Journal of the National Cancer Institute·Mitch DowsettUNKNOWN IMPACT Trialists Group
Jun 9, 2007·Breast Cancer Research : BCR·Alan MackayMitch Dowsett
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E SmithMitch Dowsett
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Feb 12, 2008·Breast Cancer Research and Treatment·J Michael DixonWilliam R Miller
Apr 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ZoubirF Andre
Apr 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaHope S Rugo
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Chad J CreightonJenny C Chang
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Massimo CristofanilliPatrick J Magill
Jan 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·C Kent OsborneMark Sellers
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Feb 4, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Antonio Llombart-CussacVicente Guillem Porta
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jun 23, 2012·Nature·Matthew J EllisElaine R Mardis
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Jan 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul E GossLois E Shepherd
Feb 9, 2013·The Journal of Clinical Investigation·Neil E BholaCarlos L Arteaga
Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C DenkertG von Minckwitz
Nov 10, 2013·Journal of the National Cancer Institute·Mei-Yin C PolleyUNKNOWN International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group
Dec 10, 2013·Journal of the National Cancer Institute·Angelo Di LeoMiguel Martin
Feb 25, 2014·Breast Cancer Research and Treatment·Robert CarpenterAnthony I Skene
Apr 8, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J L MorganL Wyld
Jun 3, 2014·The New England Journal of Medicine·Olivia PaganiUNKNOWN International Breast Cancer Study Group
Nov 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SheriM Dowsett
Nov 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexandra LearyMitch Dowsett

❮ Previous
Next ❯

Citations

Dec 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia DellapasquaUNKNOWN International Breast Cancer Study Group
Mar 1, 2019·Breast Cancer : Basic and Clinical Research·Cigdem Selli, Andrew H Sims
Apr 18, 2018·Current Treatment Options in Oncology·Tomás ReinertMatthew J Ellis
Oct 22, 2019·Frontiers in Bioengineering and Biotechnology·Rokshana S GereadApril Khademi
Sep 5, 2019·NPJ Breast Cancer·Antonio Marra, Giuseppe Curigliano
Apr 18, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Annemarie E M PostPaul N Span
Jun 3, 2021·Cancers·Covadonga Martí, José Ignacio Sánchez-Méndez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Rodrigo GoncalvesMatthew J Ellis
Current Oncology Reports
Laila S Agrawal, Ingrid A Mayer
© 2022 Meta ULC. All rights reserved